Exiris Exiris
  • About Us
    • Company Profile
    • Management Team
    • Team
    • Board of Directors
    • Scientific Advisors
    • Publications & Patents
  • Technologies
    • Antibody ID
    • Drug Conjugate
    • Cancer Stem Cell
    • Ex-Plore
  • Drug Discovery Pipeline
  • Services
    • Platform Technologies
    • Biomarker Discovery
    • Human Skin Equivalents
    • Drug Development Services
  • News
  • Contacts
    • Job Opportunities
Exiris Exiris
  • About Us
    • Company Profile
    • Management Team
    • Team
    • Board of Directors
    • Scientific Advisors
    • Publications & Patents
  • Technologies
    • Antibody ID
    • Drug Conjugate
    • Cancer Stem Cell
    • Ex-Plore
  • Drug Discovery Pipeline
  • Services
    • Platform Technologies
    • Biomarker Discovery
    • Human Skin Equivalents
    • Drug Development Services
  • News
  • Contacts
    • Job Opportunities
Oct 15

Exiris signs agreements with the Italian Institute of Health (ISS) and with Aldevron

  • 15th October 2015
  • News

Exiris signs agreements with the Italian Institute of Health (ISS) and with Aldevron on the development of novel anticancer agents.
According to two separate agreements, Exiris acquires exclusive rights to, and will pursue the development of, antibody therapeutics that were jointly discovered with ISS and Aldevron during the Eurotransbio-funded ColCab project. Aldevron and ISS will both be eligible for royalty payments on any income arising to Exiris from the commercial exploitation of these agents.

  • Facebook
  • Twitter
  • Google+
  • LinkedIn
  • E-Mail

Comments are closed.

Latest News

  • Exiris @ RaiNews24
  • Exiris presents a “High Complexity-High Efficiency Human Antibody Phage Display Library” at the Festival of Biologics (FOB) 2019, Basel 15-17 October 2019
  • Exiris receives European Union research grant for the ETN MAGICBULLET RELOADED project
  • New data presented at the 35th European Peptide Symposium, 35EPS, Dublin 26th-31st August 2018
  • New data presented at the Peptides and Conjugates for Tumor Targeting, Therapy and Diagnosis, Riminipeptide2018 Congress
  • Exiris is awarded a grant from Regione Lazio LIFE 2020
  • Exiris files patent application on novel cancer therapeutic antibodies
  • New data presented at the 7th Annual World ADC Berlin 2017
  • Exiris @ Presa Diretta
  • Exiris signs agreements with the Italian Institute of Health (ISS) and with Aldevron
© 2016 Exiris Srl · P.IVA 10897561006